Replimune Group, Inc. (REPL) Q4 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good morning and welcome to the REPLIMUNE fiscal year fourth quarter 2025 financial results and corporate update conference call. Currently, all participants are on listen-only mode. This call is being webcast live on the investors and media section of REPLIMUNE's website at REPLIMUNE.com, and a recording will be available after the call. I would like to introduce Arlene Goldenberg from REPLIMUNE. Please go ahead. Thank you, operator, and good morning, everyone. Thank you for joining us today for a discussion of Replicant's fiscal year fourth quarter 2025 business highlights and financial results. Leading the call today will be Sushil Patel, our Chief Executive Officer. He will be joined by Chris Sarkey, our Chief Commercial Officer, and Emily Hill, our Chief Financial Officer. After our prepared remarks, we will open the call for Q&A. An audio recording and webcast replay for today's conference call will also be available online as detailed in the press release announcement for this call. During today's call, we will be making certain forward-looking statements, including, without limitation, statements about the potential safety, efficacy, and regulatory and clinical progress of our product candidates, our anticipated cash runway, and our future expectations plans, partnerships, and prospects. These statements are subject to various risks, such as changes in market conditions and difficulties associated with research and development and regulatory approval processes. These and other risk factors are described in the filings made with the SEC, including our annual report on Form 10-K and our Form 10-Q filed today. Forward-looking statements are based on the assumptions, opinions, and estimates of management at the date the statements are made, including the non-occu...